Claims

Prediction · Other

“Based on our due diligence, we believe that FDA approval is likely, with blockbuster potential beyond Alcon's own commercial targets.”

Pershing Square Holdings, Investment Manager letter · 12 August 2026 · Pershing Square H1 2026 Letter To Shareholders (Seeking Alpha)

The FDA will likely approve Alcon's AURN001, with blockbuster potential beyond Alcon's commercial targets.

Not yet due The date it refers to has not come.

The second judge would not resolve this claim; the verdict shown is the first judge's.

Said for an organisation they lead or work for; it counts on both records.

What would count as true or false

The claim's main testable content is FDA approval of AURN001 (Alcon's cell therapy for corneal endothelial disease). The 'blockbuster potential' part is a hedged view of potential and is secondary. TRUE: the FDA approved AURN001 for its intended indication. MOSTLY TRUE: the FDA approved it with a materially narrower indication or significant restrictions. MOSTLY FALSE: approval came only after a Complete Response Letter and a substantial resubmission delay. FALSE: the FDA issued a Complete Response Letter that was not later overcome, refused approval, or Alcon withdrew or abandoned the application. If sales data becomes available later, sales far below blockbuster scale (under about $1 billion a year at peak) can lower a TRUE to MOSTLY TRUE, but approval drives the verdict.

Evidence

1. Aurion Biotech Completes Enrollment in Pivotal ASTRA Phase 3 Study, Advancing AURN001 Toward Potential New Treatment for Corneal Edema Secondary to Corneal Endothelial Dysfunction BioSpace (Business Wire press release from Aurion Biotech) · 23 September 2026

   “Full enrollment reached across 12 U.S. sites; a key milestone toward the planned U.S. BLA submission”

2. Aurion Biotech Completes Enrollment in Pivotal ASTRA Phase 3 Study, Advancing AURN001 Toward Potential New Treatment for Corneal Edema Secondary to Corneal Endothelial Dysfunction BioSpace (Business Wire press release from Aurion Biotech) · 23 September 2026

   “AURN001 has the potential to be the first cell therapy approved in the U.S. to treat this condition.”

3. Alcon claims control of cell therapy firm Aurion pharmaphorum · 4 November 2026

   “The cell therapy – which consists of allogeneic human corneal endothelial cells (neltependocel) and a rho kinase inhibitor (Y-27632) – has already been approved for marketing in Japan, its first market, as a treatment for corneal disorder bullous keratopathy.”

4. Aurion Biotech Doses First Patients in US Phase 3 Trial of Regenerative Cell Therapy for Corneal Disease - Eyewire+ Eyewire+ (Bryn Mawr Communications) · 4 August 2026

   “The trial is a critical step toward US regulatory approval”

Reasoning

As of September 2026, Aurion had only just finished enrolling patients in the pivotal Phase 3 ASTRA trial, and the U.S. BLA submission was still described as planned (E1, E2). In November 2026, AURN001 was reported as approved in Japan, with no U.S. FDA decision or Complete Response Letter reported (E3, E4). The claim has no deadline and none of the evidence reports an FDA decision; as of September 2026 the U.S. BLA submission was still described as planned [E1], so the outcome is not yet settled.

Cite this claim

Bill Ackman, “The FDA will likely approve Alcon's AURN001, with blockbuster potential beyond Alcon's commercial targets.” (said 12 August 2026). Verdict: not yet due. Reliability API, claim c_0b2c9f70fbbd, method 0.1.0+c876030c. https://epistacklabs.com/claims/c_0b2c9f70fbbd